Interferon Beta Drugs Market Value Anticipated To Reach US$ 4,827.6 Million By 2027: Acumen Research And Consulting
05 févr. 2021 12h52 HE
|
Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Interferon Beta Drugs Market– Global Industry Analysis, Market Size, Opportunities...
ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults*
29 janv. 2021 12h20 HE
|
Arvelle Therapeutics
Positive CHMP opinion is an important milestone for Arvelle Therapeutics and cenobamate When approved, cenobamate will provide new hope in helping adult patients with uncontrolled focal epilepsy move...
InvestorBrandNetwork Announces C3 Chat Show Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco
13 janv. 2021 08h30 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Jan. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...
InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President & CEO James Sapirstein
24 nov. 2020 08h17 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Nov. 24, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment...
Receptor Life Sciences Receives Schedule I Research License from U.S. Drug Enforcement Agency
16 nov. 2020 08h00 HE
|
Receptor Holding
SEATTLE, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Receptor Life Sciences announced today that the Company was granted a Schedule I research license from the United States Drug Enforcement Agency (DEA). ...
Immunophotonics Announces First Patient Treated in Clinical Study Evaluating IP-001 in Patients with Advanced Solid Tumors
10 nov. 2020 01h08 HE
|
Immunophotonics, Inc.
ST. LOUIS and BERN, Switzerland, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. announces the first patient treated in the phase 1b/2a clinical trial examining IP-001 in thermally ablated...
InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring VistaGen Therapeutics Inc. CEO Shawn Singh
27 oct. 2020 08h17 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, Oct. 27, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment...
Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors
05 oct. 2020 10h13 HE
|
ImmunoPhotonics, Inc.
ST. LOUIS, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers for the...
Immunophotonics Announces Appointment of Jonathan Knowles to Board of Directors
05 oct. 2020 04h13 HE
|
ImmunoPhotonics, Inc.
BERN, Switzerland, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Immunophotonics, Inc., a biotechnology company focused on the discovery and development of proprietary immune-activating carbohydrate polymers...
FDA Granted Pediatric Disease Designation for OXi-4503
16 sept. 2020 07h00 HE
|
Mateon Therapeutics, Inc.
-Treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients AGOURA HILLS, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics...